Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

  • STATUS
    Recruiting
  • End date
    May 31, 2025
  • participants needed
    150
  • sponsor
    M.D. Anderson Cancer Center
Updated on 7 October 2022
vasectomy
cancer
tubal ligation
measurable disease
gilbert's syndrome
neutrophil count
tumor cells
pembrolizumab
vaccine therapy
biomarker analysis
solid tumors
cancer chemotherapy
adenocarcinoma
cfdna
tumor marker
metastatic pancreatic ductal adenocarcinoma
pancreatic ductal adenocarcinoma
breast ductal carcinoma
ca19-9
carbohydrate antigen 19.9

Summary

This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing or kill them.

Description

PRIMARY OBJECTIVES:

I. Demonstrate that developing a custom vaccine for metastatic pancreatic ductal adenocarcinoma (PDA) and colorectal cancer (CRC) patients is feasible. (cohorts A and B)

II. Show that a custom peptide-based vaccine in combination with imiquiomod, pembrolizumab, and/or sotigalimab (APX005M) is safe. (cohorts A and B and C and D)

SECONDARY OBJECTIVES:

I. Determine the clinical benefit of the peptide vaccine alone or combined with pembrolizumab or pembrolizumab and APX005M. (cohorts A and B and C and D)

II. Demonstrate the antigenicity of each vaccine. (cohorts A and B and C and D)

III. The change in neoantigen-specific T cell responses at 12 weeks after initiation of personalized peptide vaccination. (cohorts C and D)

IV. Relapse-free survival and circulating tumor deoxyribonucleic acid (ctDNA) clearance rate. (cohorts C and D)

OUTLINE: Patients are assigned to 1 of 3 cohorts.

COHORT A: Patients receive personalized synthetic tumor-associated peptide vaccine therapy subcutaneously (SC) on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients then receive imiquimod cream topically in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.

COHORT B: Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab intravenously (IV) over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.

COHORTS C AND D: Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 9, 12, 15, 18, 21, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab IV over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Beginning about 1 hour after each vaccine, patients also receive sotigalimab IV over 60 minutes on day 1 of weeks 0, 1, 3, 4, 6, 9, 12, 15, 18, 21, and 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and weeks 6,12, and 24, then every 3 months, and at week 39.

After completion of study treatment, patients are followed for 6 months.

Details
Condition Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Treatment laboratory biomarker analysis, computed tomography, magnetic resonance imaging, Pembrolizumab, Imiquimod, Phone Call, Peptide Vaccine, Peptide Vaccine, Synthetic Tumor-Associated Peptide Vaccine Therapy, Sotigalimab
Clinical Study IdentifierNCT02600949
SponsorM.D. Anderson Cancer Center
Last Modified on7 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

COHORTS A AND B: Patients must have metastatic pancreatic ductal adenocarcinoma (PDA) or metastatic colorectal cancer (CRC) to be eligible (PDA patients with an elevated tumor marker following a primary pancreatic surgery would be eligible)
Patients can have any lines (including zero) of prior therapy to sign consent prior to tissue harvest; vaccination will not take place until at least one line of standard chemotherapy is given
Patients must have adequate fresh or frozen tissue available or planned to be obtained; for cohort C and D patients should have estimated adequate tumor tissue that is planned to be resected (approximately > 1 cm cross-sectional size on radiographic imaging); subjects may have tissue collected under protocol PA15-0176
Age >= 18 years
Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
Life expectancy of greater than 6 months (12 months for cohort C and 9 months for cohort D)
Absolute neutrophil count (ANC) >= 1,000/mcL
Platelets >= 75,000/mcL
Total bilirubin =< 2.0 x institutional upper limit of normal
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (=< 5 X if known liver metastases or due to ongoing chemotherapy treatment defined as chemotherapy within 3 weeks prior to lab draw) (except in Gilbert's disease where direct bilirubin will be used)
Calculated creatinine clearance >= 40 mL/min/1.73 m^2
Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document
The effects of a peptide-based vaccine, pembrolizumab or APX005M on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception at study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; birth control specifications: unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), sexually active participants must use birth control during and for > 120 days after the study; abstinence is also an acceptable form of birth control
FOR COHORT C ONLY: Patients must have metastatic colorectal cancer (CRC) and are planned to or have undergone complete (R0 or R1) metastectomy/ies (liver or peritoneal or lung or other organ site); the presence of nonspecific lung lesions < 1 cm are allowed
FOR COHORT C ONLY: Agreement to have post-operative blood test to determine plasma mutation ctDNA positivity drawn within 6 weeks following surgical resection
FOR COHORT D ONLY: Patients must have localized or metastatic PDA and are planned for complete resection (R0 or R1)
FOR COHORT D ONLY: Agreement to have post-operative blood test to determine plasma mutation ctDNA positivity drawn within 6 weeks following surgical resection
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): ECOG performance status 0-1 (Karnofsky >= 60%)
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): Life expectancy of greater than 6 months
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): Patients must have either measurable disease per Response Criteria in Solid Tumors (RECIST) version (v)1.1 or evaluable disease defined as an elevated tumor biomarker (CA19-9, carcinoembryonic antigen [CEA] or ctDNA mutation); pancreatic cancer patients with an elevated tumor marker following a primary pancreatic surgery would be eligible (cohorts A and B only)
FOR COHORT C AND D ONLY: Patients must have plasma mutation ctDNA positivity within 6 weeks following surgical resection or ctDNA positivity on any serial testing timepoint if the initial ctDNA timepoint was negative or testing failure occurred
FOR COHORT C AND D ONLY: Completion of all planned adjuvant anti-cancer therapy
An elevated CA19-9 (above MDACC upper limit of normal, > 35 U/ml) will serve as a ctDNA positive equivalent (Cohort D only)
FOR COHORT C AND D ONLY: Radiographic disease status is not relevant to inclusion for treatment

Exclusion Criteria

Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for lack of efficacy of therapeutic cancer vaccine
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
Subjects with active, known or suspected autoimmune disease; subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Women of child bearing potential who are pregnant or breastfeeding; women with a positive pregnancy test at enrollment or prior to administration of vaccine
Has history of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis
Known history of active TB (Bacillus tuberculosis)
Has a known additional malignancy that is progressing or requires active treatment
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS)
Hypersensitivity to vaccine, pembrolizumab, imiquimod or APX005M or any of its excipients
Women of child bearing potential who are pregnant or breastfeeding
Women with a positive pregnancy test prior to administration of vaccine
Active coagulopathy
History of arterial thrombosis within 3 months of starting study treatment
History of New York Heart Association class 3-4 heart failure or myocardial infarction within 6 months of starting therapy
Has a known history of hepatitis B (defined as being known hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as being known hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] positive) infection
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): Patients who have had chemotherapy or radiotherapy within 2 weeks prior to first treatment or those who have not recovered to baseline from adverse events due to agents administered more than 2 weeks earlier (washout period)
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): Uncontrolled concurrent illness
including, but not limited to ongoing or active infection, symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance with study
requirements
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): Patients may not be receiving any other investigational agents within 2 weeks prior to first treatment
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): Has received a live vaccine within 30 days of planned start of study therapy Note: Seasonal influenza vaccines and COVID-19 vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note